Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Part of paid clinical trials in San Francisco, California.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT04626479
Phase
PHASE1/PHASE2
Status
Active Not Recruiting

Conditions

  • Carcinoma, Renal Cell

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — BIOLOGICAL
    Administered via IV infusion at a dose of 400 mg Q6W
  • Favezelimab/Pembrolizumab — BIOLOGICAL
    Administered via IV infusion at a dose of 800 mg/200 mg Q3W
  • Belzutifan — DRUG
    Administered via oral tablet at a dose of 120 mg QD
  • Lenvatinib — DRUG
    Administered via oral capsule at a dose of 20 mg QD
  • Pembrolizumab/Quavonlimab — BIOLOGICAL
    Administered via IV infusion at a dose of 400 mg/25 mg Q6W
  • Vibostolimab/Pembrolizumab — DRUG
    Administered via IV infusion at a dose of 200 mg/200 mg Q6W

Study Details

Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first line (1L) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.

Key Dates

First listed
Nov 12, 2020
Start date
Dec 16, 2020
Status verified
May 2026
Primary completion
Jul 17, 2026
Completion
Jul 17, 2026

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Coformulation Pembrolizumab/Quavonlimab + Lenvatinib
    Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab 400 mg and quavonlimab 25 mg) PLUS lenvatinib 20 mg. Pembrolizumab/quavonlimab will be administered intravenously (IV) once every 6 weeks (Q6W) for up to 17 administrations (up to \~2 years). Lenvatinib will be administered orally once-daily (QD) until progressive disease or discontinuation.
  • Experimental: Coformulation Favezelimab/Pembrolizumab+ Lenvatinib
    Participants will receive favezelimab/pembrolizumab (coformulation of favezelimab 800 mg and pembrolizumab 200 mg) PLUS lenvatinib 20 mg. Favezelimab/Pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
  • Experimental: Pembrolizumab + Belzutifan + Lenvatinib
    Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~2 years). Both belzutifan and lenvatinib will be administered orally QD until progressive disease or discontinuation.
  • Experimental: Pembrolizumab + Lenvatinib
    Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~ 2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
  • Experimental: Coformulation Vibostolimab/Pembrolizumab+Belzutifan
    Participants will receive vibostolimab/pembrolizumab (coformulation of 200 mg vibostolimab and pembrolizumab 200 mg). Vibostolimab/pembrolizumab will be administered IV once every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Belzutifan will be administered orally QD until progressive disease or discontinuation.

Primary Outcome Measure

Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs) [ Time Frame: Up to ~21 days ]

Locations (10)

FacilityCityStateZIPSite coordinators
University of California at San Francisco ( Site 1008)San FranciscoCalifornia94158-
Yale-New Haven Hospital-Yale Cancer Center ( Site 1011)New HavenConnecticut06510-
University of Chicago ( Site 1013)ChicagoIllinois60637-
University of Iowa ( Site 1012)Iowa CityIowa52242-
Henry Ford Health System ( Site 1014)DetroitMichigan48202-
Laura and Isaac Perlmutter Cancer Center ( Site 1016)New YorkNew York10016-
Memorial Sloan Kettering Cancer Center ( Site 1002)New YorkNew York10065-
Duke Cancer Institute ( Site 1015)DurhamNorth Carolina27710-
UPMC Cancer Center/Hillman Cancer Center ( Site 1017)PittsburghPennsylvania15232-
UTSW Medical Center ( Site 1003)DallasTexas75390-

Find similar trials in San Francisco, CA

By research site
University of California at San Francisco· San Francisco, CAYale-New Haven Hospital-Yale Cancer Center· New Haven, CTUniversity of Chicago· Chicago, ILUniversity of Iowa· Iowa City, IAHenry Ford Health System· Detroit, MILaura and Isaac Perlmutter Cancer Center· New York, NY

Related Studies